Sarepta Therapeutics, Inc.
Adeno-Associated Virus Vector Delivery for Muscular Dystrophies

Abstract:

The disclosure provides method of treating muscular dystrophy in a subject in need comprising administering a gene therapy vector, such as adeno-associated virus (AAV) vector, expressing a miniaturized human micro-dystrophin gene in combination with a step of suppressing the subject's immune system.